/
CELU
$0.61-$0.01 (-2.21%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$17.9M
29M shares
52-week range
$0.57 – $4.35
1% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
3.84%
Moderate
Price (6 mo)
Loading chart…
Change$-120.89
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $17.6M | $21.1M | $14.3M | $21.3M | $18.0M | $22.8M | $54.2M | $26.6M |
| Cost of revenue | $6.6M | $6.3M | $4.9M | $9.7M | $19.7M | $16.0M | $15.0M | $6.4M |
| Gross profit | $11.0M | $14.8M | $9.3M | $11.7M | −$1.7M | $6.8M | $39.2M | $20.2M |
| Gross margin | 62.7% | 70.1% | 65.5% | 54.8% | -9.4% | 29.7% | 72.4% | 76.0% |
| R&D | $29.1M | $46.1M | $52.7M | $88.4M | $78.4M | $30.5M | $17.4M | $15.0M |
| Operating income | −$1.1K | −$264.1M | −$151.9M | −$109.1M | −$25.6M | −$192.3M | −$38.4M | −$61.3M |
| EBITDA | −$1.1K | −$71.0M | −$202.4M | −$88.1M | −$138.8M | −$183.9M | −$43.7M | −$77.7M |
| Net income | −$1.1K | −$211.9M | −$208.2M | −$100.1M | $14.2M | −$196.3M | −$57.9M | −$91.8M |
| Net margin | -0.0% | -1001.9% | -1458.4% | -469.3% | 79.0% | -862.0% | -106.8% | -345.8% |
| EPS (diluted) | 0.00 | -88.75 | -113.06 | -7.87 | 0.95 | -11.02 | -2.64 | -3.59 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $44M | $-2.75 | $-2.75–$-2.75 | 1 |
| 2027 | $286M | $1.50 | $1.50–$1.50 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Celularity Inc. Class A Common Stock
Celularity Inc is a regenerative and cellular medicine company focused on developing placental-derived allogeneic cell therapies and biomaterial products for the treatment of degenerative diseases, aging-related conditions, cancer, and immune disorders. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It generates the majority of its revenue from the Degenerative Disease segment.
www.celularity.com- Employees
- 115
- IPO / List date
- Jul 19, 2021
- HQ
- FLORHAM PARK, NJ
Held by traders on TradeandTell
No one on the platform currently holds CELU.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-09-30 | 42,000 | $86.9K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2024-02-29 | 1-for-10reverse |
Recent trades on TradeandTell
No one on the platform has traded CELU yet.
